Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 18/20 | 1.00 |
| ▸ | KCNJ3 | P48549 | 18/20 | 1.00 |
| ▸ | KCNJ5 | P48544 | 13/20 | 0.92 |
| ▸ | BRAF | P15056 | 1/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234482 | 0.89 | KCNJ6 (0.84) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4937639 | 0.89 | KCNJ6 (0.80) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL4932003 | 0.88 | KCNJ6 (0.78) | KCNJ6KCNJ3KCNJ5BRAFMAPK13 | |
| SCHEMBL13234480 | 0.87 | KCNJ6 (0.76) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL13234630 | 0.86 | KCNJ6 (0.75) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL4938157 | 0.86 | KCNJ6 (0.75) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL13234475 | 0.86 | KCNJ6 (0.92) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13200910 | 0.83 | KCNJ6 (0.71) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL25793174 | 0.79 | KCNJ6 (0.69) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4513114 | 0.79 | KCNJ6 (0.72) | KCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | claimed |
| EP-1831228-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068591-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1831228-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068591-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | CHRM2, CHRNA1, CHRM1 | KCNJ6 720/4885KCNJ3 654/4885KCNJ5 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.